The companies are also running an open-label study to evaluate the long-term efficacy and safety of the therapy.

Positive study results in Phase 2 lead to a green light for the companies’ combination and plans to move their nasal spray ...

BPL-003 showed “robust” efficacy data in treatment-resistant depression, according to analysts from Jefferies, who noted that the asset could hit peak market sales of $1 billion. The results clear the ...

Premature babies often need help breathing as their lungs are not fully developed. Nasal breathing support (through the nose) helps premature babies breathe without the need for breathing tubes in the ...